H.C. Wainwright analyst Oren Livnat raised the firm’s price target on Avadel Pharmaceuticals to $21 from $17.50 and keeps a Buy rating on the shares. The firm says the Lumryz launch is going faster than expected. Management’s expected market growth and market share make Wainwright’s peak estimates look very conservative, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on AVDL:
- Avadel Pharmaceuticals price target raised to $18 from $16 at Craig-Hallum
- Avadel Pharmaceuticals price target raised to $25 from $22 at Oppenheimer
- Avadel Pharmaceuticals to Host Commercial Day on June 29 for LUMRYZ™ (sodium oxybate) extended release for oral solution, CIII
- Avadel Pharmaceuticals sponsors AASM Foundation’s 2023 YIRF
- Avadel Pharmaceuticals Sponsors the Academy of Sleep Medicine Foundation’s 2023 Young Investigators Research Forum